

February 26, 2014


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

| | |
|-------------------|---|
| USAN (bc-58) | AMIFAMPRIDINE PHOSPHATE |
| PRONUNCIATION | am" i fam' pri deen |
| THERAPEUTIC CLAIM | Treatment of Lambert Eaton Myasthenic Syndrome (LEMS) |

CHEMICAL NAMES

1. 3,4-Pyridinediamine, phosphate (1:1)
2. Pyridine-3,4-diamine monophosphate

STRUCTURAL FORMULA



| | |
|----------------------------|---|
| MOLECULAR FORMULA | C ₅ H ₇ N ₃ .H ₃ O ₄ P |
| MOLECULAR WEIGHT | 207.1 |
| TRADEMARK | Firdapse™ |
| SPONSOR | Catalyst Pharmaceutical Partners |
| CODE DESIGNATIONS | DAPP; 3,4-DAPP |
| <u>CAS</u> REGISTRY NUMBER | 446254-47-3 |
| UNII | 8HF8FIN815 |

gbk